Enterprise Value
16.0M
Cash
25.71M
Avg Qtr Burn
-6.273M
Short % of Float
0.54%
Insider Ownership
19.27%
Institutional Own.
59.64%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Auxora™ Details Acute Pancreatitis | Phase 2b Data readout | |
Auxora™ Details Asparaginase-induced pancreatic toxicity | Phase 2 Data readout | |
Auxora™ Details Acute Kidney Injury, Kidney disease | Phase 2 Data readout | |
GB-102 (Pan-VEGF inhibitor) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued | |
GB-102 (Pan-VEGF inhibitor) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |